Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients

Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight

SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.

Adding the FDA-cleared Elecsys pTau217 test to the AD-Detect™ portfolio

Earlier today, Roche announced that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, making it the first and only FDA-cleared single-assay, single-biomarker blood biomarker test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings. Quest provides a comprehensive menu of blood-based Alzheimer's biomarker tests under the AD-Detect™ brand name. Quest plans to introduce an AD-Detect-branded laboratory test service based on the FDA-cleared Elecsys® pTau217 assay to physicians and clinical trials collaborators nationwide in the fourth quarter of this year. Quest also plans to incorporate the Roche test in future AD-Detect panels in 2027.